PHILADELPHIA – In this exclusive video perspective from the American College of Gastroenterology Annual Meeting, Sophie M. Balzora, MD, FACG, gastroenterologist at the NYU School of Medicine, gives a preview of some of the key inflammatory bowel disease research to keep an eye on during the meeting.
“There’s a lot of exciting things on the horizon,” she told Healio Gastroenterology and Liver Disease. “I think both the inpatient and outpatient management of our patients will be heightened by what we find out during this conference.”
Balzora said she was particularly intrigued by a long-term study of Stelara (ustekinumab, Janssen) in patients with Crohn’s Disease.
“We have seen a lot of success in terms of patients with moderate-to-severe Crohn’s, but I think with this long-term study that goes up to 5 years out, that shows a very favorable outcome for these patients, is really fantastic,” she said. “I’m very excited to learn more about that and of course see a lot of our colleagues that have come all the way to [Philadelphia] to learn during this conference.”
: Balzora reports no relevant financial disclosures.